Immunology in the Clinic Review Series; focus on allergies: Basophils as biomarkers for assessing immune modulation

Clinical and Experimental Immunology

Volumn 167, Issue 1, 2012, Pages 59-66

  Patil, S U ^a   Shreffler, W G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Basophil; Desensitization; Immunotherapy

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN E; MEMBRANE PROTEIN; TETRASPANIN;

BASOPHIL; CELL ACTIVATION; CELL ACTIVITY; CELL KINETICS; DESENSITIZATION; EFFECTOR CELL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW;

ALLERGENS; ANIMALS; BASOPHILS; DESENSITIZATION, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; HISTAMINE RELEASE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, IGE; RECEPTORS, IGG; TREATMENT OUTCOME;

EID: 82655181552     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04503.x     Document Type: Review

References (64)

1. Sampson HA, Broadbent KR, Bernhisel-Broadbent J. Spontaneous release of histamine from basophils and histamine-releasing factor in patients with atopic dermatitis and food hypersensitivity. N Engl J Med 1989; 321:228-32.
2. Knol EF, Mul FP, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol 1991; 88:328-38.
3. Metzelaar MJ, Wijngaard PL, Peters PJ, Sixma JJ, Nieuwenhuis HK, Clevers HC. CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem 1991; 266:3239-45.
4. MacGlashan D Jr. Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes. Clin Exp Allergy 2010; 40:1365-77.
5. Buhring HJ, Seiffert M, Giesert C etal. The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. Blood 2001; 97:3303-5.
6. Monneret G, Gutowski MC, Bienvenu J. Detection of allergen-induced basophil activation by expression of CD63 antigen using a tricolour flow cytometric method. Clin Exp Immunol 1999; 115:393-6.
7. Hennersdorf F, Florian S, Jakob A etal. Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Res 2005; 15:325-35.
8. Gober LM, Eckman JA, Sterba PM etal. Expression of activation markers on basophils in a controlled model of anaphylaxis. J Allergy Clin Immunol 2007; 119:1181-8.
9. Kleine-Tebbe J, Erdmann S, Knol EF, MacGlashan DW Jr, Poulsen LK, Gibbs BF. Diagnostic tests based on human basophils: potentials, pitfalls and perspectives. Int Arch Allergy Immunol 2006; 141:79-90.
10. Shreffler WG. Evaluation of basophil activation in food allergy: present and future applications. Curr Opin Allergy Clin Immunol 2006; 6:226-33.
11. Mousallem T, Burks A. Immunotherapy for Food Allergy. Clin Exp Immunol 2012; 167:26-31.
12. Krishna MT, Huissoon AP. Clinical immunology review series: an approach to desensitization. Clin Exp Immunol 2011; 163:131-46.
13. Nopp A, Cardell LO, Johansson SG, Oman H. CD-sens: a biological measure of immunological changes stimulated by ASIT. Allergy 2009; 64:811-14.
14. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; (1):CD001936.
15. Ebo DG, Hagendorens MM, Schuerwegh AJ etal. Flow-assisted quantification of in vitro activated basophils in the diagnosis of wasp venom allergy and follow-up of wasp venom immunotherapy. Clin Cytom 2007; 72:196-203.
16. Kim EH, Bird JA, Kulis M etal. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol 2011; 127:640-6 e1.
17. Jones SM, Pons L, Roberts JL etal. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009; 124:292-300, e1-97.
18. Mikkelsen S, Bibby BM, Dolberg MK, Dahl R, Hoffmann HJ. Basophil sensitivity through CD63 or CD203c is a functional measure for specific immunotherapy. Clin Mol Allergy 2010; 8:2-9.
19. Schubert R, Eickmeier O, Garn H etal. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol 2009; 148:251-60.
20. Fujisawa T, Nagao M, Hiraguchi Y etal. Biomarkers for allergen immunotherapy in cedar pollinosis. Allergol Int 2009; 58:163-70.
21. Eberlein-Konig B, Ullmann S, Thomas P, Przybilla B. Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization. Clin Exp Allergy 1995; 25:704-12.
22. Kucera P, Cvackova M, Hulikova K, Juzova O, Pachl J. Basophil activation can predict clinical sensitivity in patients after venom immunotherapy. J Inves Allergol Clin Immunol 2010; 20:110-16.
23. Peternelj A, Silar M, Erzen R, Kosnik M, Korosec P. Basophil sensitivity in patients not responding to venom immunotherapy. Int Arch Allergy Immunol 2008; 146:248-54.
24. Kosnik M, Silar M, Bajrovic N, Music E, Korosec P. High sensitivity of basophils predicts side-effects in venom immunotherapy. Allergy 2005; 60:1401-6.
25. Korosec P, Kosnik M. Predicting side-effects in venom immunotherapy by basophil activation: basophil sensitivity vs maximal response. Allergy 2007; 62:81.
26. Eberlein-Konig B, Schmidt-Leidescher C, Behrendt H, Ring J. Predicting side-effects in venom immunotherapy by basophil activation? Allergy 2006; 61:897.
27. Eberlein-Konig B, Schmidt-Leidescher C, Rakoski J, Behrendt H, Ring J. In vitro basophil activation using CD63 expression in patients with bee and wasp venom allergy. J Invest Allergol Clin Immunol 2006; 16:5-10.
28. Plewako H, Wosinska K, Arvidsson M etal. Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int Arch Allergy Immunol 2006; 141:346-53.
29. Nagao M, Hiraguchi Y, Hosoki K etal. Allergen-induced basophil CD203c expression as a biomarker for rush immunotherapy in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol 2008; 146 (Suppl. 1):47-53.
30. Horak F, Zieglmayer P, Zieglmayer R etal. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009; 124:471-7, 7 e1.
31. Erdmann SM, Sachs B, Kwiecien R, Moll-Slodowy S, Sauer I, Merk HF. The basophil activation test in wasp venom allergy: sensitivity, specificity and monitoring specific immunotherapy. Allergy 2004; 59:1102-9.
32. Brown SG, Haas MA, Black JA, Parameswaran A, Woods GM, Heddle RJ. In vitro testing to diagnose venom allergy and monitor immunotherapy: a placebo-controlled, crossover trial. Clin Exp Allergy 2004; 34:792-800.
33. Jutel M, Muller UR, Fricker M, Rihs S, Pichler WJ, Dahinden C. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy 1996; 26:1112-18.
34. Siegmund R, Vogelsang H, Machnik A, Herrmann D. Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy. J Allergy Clin Immunol 2000; 106:1190-5.
35. Ceuppens JL, Bullens D, Kleinjans H, van der Werf J. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects. Clin Exp Allergy 2009; 39:1903-9.
36. Malveaux FJ, Conroy MC, Adkinson NF Jr, Lichtenstein LM. IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest 1978; 62:176-81.
37. Christensen LH, Holm J, Lund G, Riise E, Lund K. Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge. J Allergy Clin Immunol 2008; 122:298-304.
38. Lalek N, Kosnik M, Silar M, Korosec P. Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy. Clin Exp Allergy 2010; 40:1186-93.
39. Gadermaier E, Staikuniene J, Scheiblhofer S etal. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5years of discontinuation. Allergy 2011; 66:1174-82.
40. Francis JN, James LK, Paraskevopoulos G etal. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121:1120-5 e2.
41. Golden DB, Meyers DA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol 1982; 69:489-93.
42. Muller U, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 1989; 44:412-18.
43. Ejrnaes AM, Svenson M, Lund G, Larsen JN, Jacobi H. Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy -induced serum immunoglobulin G: no evidence that FcgammaRIIB signalling is important. Clin Exp Allergy 2006; 36:273-82.
44. Wurtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy 2008; 38:1290-301.
45. Flicker S, Steinberger P, Norderhaug L etal. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol 2002; 32:2156-62.
46. James LK, Shamji MH, Walker SM etal. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011; 127:509-16 e1-5.
47. Scadding GW, Shamji MH, Jacobson MR etal. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606.
48. Uermosi C, Beerli RR, Bauer M etal. Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol 2010; 126:375-83.
49. Michils A, Ledent C, Mairesse M, Gossart B, Duchateau J. Wasp venom immunotherapy changes IgG antibody specificity. Clin Exp Allergy 1997; 27:1036-42.
50. Cady CT, Powell MS, Harbeck RJ etal. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. Immunol Lett 2010; 130:57-65.
51. Kepley CL, Cambier JC, Morel PA etal. Negative regulation of FcepsilonRI signaling by FcgammaRII costimulation in human blood basophils. J Allergy Clin Immunol 2000; 106:337-48.
52. Wigginton SJ, Furtado PB, Armour KL etal. An immunoglobulin E-reactive chimeric human immunoglobulin G1 anti-idiotype inhibits basophil degranulation through cross-linking of FcepsilonRI with FcgammaRIIb. Clin Exp Allergy 2008; 38:313-19.
53. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 2002; 8:518-21.
54. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11:446-9.
55. Kepley CL, Youssef L, Andrews RP, Wilson BS, Oliver JM. Syk deficiency in nonreleaser basophils. J Allergy Clin Immunol 1999; 104:279-84.
56. MacGlashan DW Jr. Relationship between spleen tyrosine kinase and phosphatidylinositol 5' phosphatase expression and secretion from human basophils in the general population. J Allergy Clin Immunol 2007; 119:626-33.
57. Vilarino N, MacGlashan DW Jr. Actin cytoskeleton-dependent down-regulation of early IgE-mediated signaling in human basophils. J Leukoc Biol 2004; 75:928-37.
58. Kepley CL. Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels. Int Arch Allergy Immunol 2005; 138:29-39.
59. MacGlashan D Jr, Vilarino N. Polymerization of actin does not regulate desensitization in human basophils. J Leukoc Biol 2009; 85:627-37.
60. Lund G, Jacobi H, Skov PS, Holm J, Lund K. Effect on cell surface markers following allergen-induced desensitization of human whole-blood basophils. Int Arch Allergy Immunol 2010; 153:323-34.
61. MacGlashan D Jr, Undem BJ. Inducing an anergic state in mast cells and basophils without secretion. J Allergy Clin Immunol 2008; 121:1500-6, 6 e1-4.
62. Sancho-Serra Mdel C, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcepsilonRI internalization. Eur J Immunol 2011; 41:1004-13.
63. MacGlashan DW Jr. Endocytosis, recycling, and degradation of unoccupied FcepsilonRI in human basophils. J Leukoc Biol 2007; 82:1003-10.
64. Paterniti M, Kelly DC, Eckman JA etal. Cat allergen-induced blood basophil reactivity in vitro predicts acute human nasal allergen challenge responses in vivo. Clin Exp Allergy 2011; 41:963-9.